Copyright
©The Author(s) 2022.
World J Gastrointest Endosc. Mar 16, 2022; 14(3): 153-162
Published online Mar 16, 2022. doi: 10.4253/wjge.v14.i3.153
Published online Mar 16, 2022. doi: 10.4253/wjge.v14.i3.153
Table 3 Severe acute respiratory syndrome coronavirus 2 IgG positive inflammatory bowel disease patients divided by presence or absence of COVID-19 symptoms and ongoing therapy
| SARS-CoV-2 IgG value > 7 | ||||
| SARS-CoV-2 IgG positive patients (n, %) | Therapy (patients, n, %) | Disease | Total n (%) | |
| CD (n) | UC (n) | |||
| COVID-19 symptoms yes (12, 63.2) | Biologic drug (6, 50.0) | 5 | 1 | 6 |
| Azathioprine (4, 33.3) | 1 | 3 | 4 | |
| Mesalazine (2, 16.6) | 0 | 2 | 2 | |
| COVID-19 symptoms no (7, 36.8) | Biologic treatment (4, 57.1) | 4 | 0 | 4 |
| Azathioprine (1, 14.3) | 0 | 1 | 1 | |
| Mesalazine (2, 28.6) | 0 | 2 | 2 | |
| 12 | 7 | 19 | ||
- Citation: Conti CB, Mainardi E, Soro S, Testa S, De Silvestri A, Drago A, Cereatti F, Grassia R. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy. World J Gastrointest Endosc 2022; 14(3): 153-162
- URL: https://www.wjgnet.com/1948-5190/full/v14/i3/153.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i3.153